HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Leverages Power Of Digital Personalization With Nicorette UK Extension

Executive Summary

Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.

You may also be interested in...



Kenvue Joins Digital Gut Health Revolution With UK Imodium App

Kenvue’s new Gut2Know app “empowers diarrhea sufferers to boost their gut knowledge and track and identify triggers for their symptoms, such as stress or diet,” the company says. With the launch, Kenvue joins other major players like Bayer and Sanofi who have recently invested in digital digestive health.

UK Product Approvals: J&J Expands Sudafed And Nicorette Offerings

The UK's MHRA has approved the Rx-to-OTC switch of J&J's Sudafed Plus nasal spray (xylometazoline hydrochloride/dexpanthenol) and given the green light for the company to add new pack sizes to its Nicorette QuickMist and QuickMist Smart Track products.

AESGP Annual Meeting, Day 2: Communicating Risk, E-Commerce Boom, RWE And Sustainability

Day two of the AESGP's 57th Annual Meeting featured discussions on communicating risk in times of uncertainty, how to foster a harmonized EU market for food supplements and the growth of the ePharmacy channel. The opportunities presented by real-world evidence were also debated, along with the challenges facing the self-care industry in the area of sustainability.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150743

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel